Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis.
Tammy JiangTjalf ZiemssenSibyl WrayChangyu ShenKarin SöderbärgJames B LewinIvan BožinMark S FreedmanPublished in: CNS drugs (2023)
EVOLVE-MS-1 (ClinicalTrials.gov identifier: NCT02634307); OPTIMUM (ClinicalTrials.gov identifier: NCT02425644).